tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva]
tiopronin
RxCUI: 2702684
What the CMS Formulary Data Shows for tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva]
Per the CMS 2026 Part D formulary file, tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] (RxNorm concept RXCUI 2702684, generic name tiopronin) appears on 12 distinct formulary files spanning 161 Medicare Part D plan offerings - 3.2% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.
Real-world access to tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] depends on utilization management as much as tier placement: 25% of covering formularies require prior authorization. 0% require step therapy. 0% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 261 Part D beneficiaries filled tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] in 2023, with total plan-and-beneficiary spending of $23,230,085 and an average per-beneficiary annual cost of $89,004.16. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] today.
Coverage Details
- Formularies covering
- 12
- Plans covering
- 161
- Coverage rate
- 3.2%
- Tier range
- Tier 1 – Tier 5
- Average tier
- Tier 4, Non-Preferred
Restrictions
- Prior authorization required
- 25% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 0% of formularies
2023 Medicare Spending
- Beneficiaries
- 261
- Total spending
- $23,230,085
- Avg per beneficiary
- $89,004.16
Tier Distribution Across Plans
Medicare Advantage Plans (MA-PD) Covering tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva]
100 Medicare Advantage plans with Part D drug coverage include this drug.
Frequently Asked Questions
Is tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] covered by Medicare Part D?
Yes, tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] is covered by 161 Medicare Part D plans (3.2% of all Part D formularies).
What tier is tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] on Medicare Part D plans?
tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] averages Tier 4 across Part D plans, ranging from Tier 1 to Tier 5.
Does tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] require prior authorization?
25% of Part D formularies require prior authorization for tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva]. Step therapy: 0%. Quantity limits: 0%.
How much does Medicare spend on tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva]?
In 2023, total Medicare Part D spending on tiopronin 300 MG Delayed Release Oral Tablet [Venxxiva] was $23,230,085, covering 261 beneficiaries. The average spend per beneficiary was $89,004.16.
Read our methodology - how this data is sourced, computed, and verified.